Egan Brent M, Papademetriou Vasilios, Wofford Marion, Calhoun David, Fernandes Jyotika, Riehle Jessica E, Nesbitt Shawna, Michelson Eric, Julius Stevo
Medical University of South Carolina, Charleston, South Carolina, USA.
Am J Hypertens. 2005 Jan;18(1):3-12. doi: 10.1016/j.amjhyper.2004.08.008.
Although insulin resistance and metabolic syndrome are often used synonymously, concordance is not established.
Metabolic, hemodynamic, and hormonal data were analyzed on 141 patients in the Trial of Preventing Hypertension (TROPHY) Sub-Study with high-normal blood pressure (BP) (130 to 139/85 to 89 mm Hg [mean +/- SD, 133 +/- 8/85 +/- 6 mm Hg]; age, 48 +/- 9 years; body mass index 30 +/- 5 kg/m(2)).
Fifty-three of 141 subjects (37.6%; approximately 3/8) had the metabolic syndrome based on three or more of the five risk factors (BP, waist circumference, fasting triglycerides, HDL-cholesterol, glucose). To maintain consistency in proportions, insulin resistance was defined as the upper 3/8 of the distribution on the homeostatic model assessment (HOMA), which uses fasting glucose and insulin and a modified Matsuda-DeFronzo index, based on fasting, 1- and 2-h glucose and insulin values. Among metabolic syndrome patients, 57% and 55% were in the upper 3/8 of the distribution for insulin resistance by HOMA and Matsuda-DeFronzo, respectively. Among subjects without the metabolic syndrome, 26% and 27% were insulin resistant by HOMA and Matsuda-DeFronzo criteria. The proportion of patients with metabolic syndrome and insulin resistance increased strongly and similarly with increasing body mass index. However, metabolic syndrome and insulin resistance were different compared with their respective controls in the lower 5/8 of the distribution, in waist/hip ratios, fasting and 1-h insulin, HDL-cholesterol, heart rate, and systolic BP responses to exercise and plasma renin, angiotensin, and aldosterone.
The findings suggest that metabolic syndrome and insulin resistance are not synonymous anthropometrically, metabolically, hemodynamically, or hormonally in patients with high-normal BP.
尽管胰岛素抵抗和代谢综合征常被视为同义词,但两者之间的一致性尚未确立。
对预防高血压试验(TROPHY)子研究中的141例血压处于正常高值(收缩压130至139mmHg/舒张压85至89mmHg[均值±标准差,133±8/85±6mmHg];年龄48±9岁;体重指数30±5kg/m²)的患者的代谢、血流动力学和激素数据进行了分析。
141名受试者中有53名(37.6%;约八分之三)基于五个危险因素(血压、腰围、空腹甘油三酯、高密度脂蛋白胆固醇、血糖)中的三个或更多符合代谢综合征标准。为保持比例的一致性,胰岛素抵抗被定义为稳态模型评估(HOMA)分布的上八分之三,HOMA使用空腹血糖和胰岛素以及基于空腹、1小时和2小时血糖及胰岛素值的改良松田-德弗龙佐指数。在代谢综合征患者中,分别有57%和55%的患者根据HOMA和松田-德弗龙佐指数处于胰岛素抵抗分布的上八分之三。在无代谢综合征的受试者中,根据HOMA和松田-德弗龙佐标准,分别有26%和27%的人存在胰岛素抵抗。代谢综合征和胰岛素抵抗患者的比例随体重指数增加而显著且相似地增加。然而,与分布下八分之五的各自对照组相比,代谢综合征和胰岛素抵抗在腰臀比、空腹和1小时胰岛素、高密度脂蛋白胆固醇、心率以及运动和血浆肾素、血管紧张素和醛固酮的收缩压反应方面存在差异。
研究结果表明,在血压正常高值的患者中,代谢综合征和胰岛素抵抗在人体测量学、代谢、血流动力学或激素方面并非同义词。